龍蟒佰利(002601.SZ)就收購東方鋯業15.66%的股份 與中核集團簽訂正式轉讓協議
格隆匯11月8日丨龍蟒佰利(002601.SZ)公佈,2019年11月8日,公司與中國核工業集團有限公司(“中核集團”或“轉讓方”)簽訂了《關於廣東東方鋯業科技股份有限公司之股份轉讓協議》,公司擬通過協議轉讓的方式收購中核集團持有的東方鋯業(002167.SZ)9721.0818萬股人民幣普通股,佔東方鋯業總股本的15.66%,標的股份的轉讓價格約人民幣8.73億元。
此次交易完成後,中核集團將不再持有東方鋯業股份,公司將成為東方鋯業第一大股東。公司使用自有資金和銀行貸款收購標的股份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.